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Summary
We propose a method for testing any hypothesized association between a candidate allele, for which there
is a specific laboratory test, and a common chronic disease. Families in which this allele is segregating are
identified through index individuals who are homozygous or heterozygous for the allele. The sample con-
sists of the subset of identified families who also have at least one member with the common disease of
interest. For each independent family in this subset, select one person with the disease and determine if he
or she is heterozygous for the allele. The observed proportion of heterozygotes in this sample is compared
to the proportion expected on the basis of each diseased relative's null probability of being heterozygous
for the allele; this null probability depends only on the relative's relationship to the index individual and
the population allele frequency. We provide these null probabilities, develop appropriate inference proce-
dures, discuss sample size requirements, and compare this method to a standard case-control design.
Results using this method are unlikely to be influenced by confounders, systematic bias, or genetic
heterogeneity.
Introduction
Currently available molecular genetic techniques have
greatly enhanced the power of genetic and epidemio-
logic strategies used to identify specific genes that pre-
dispose to common chronic diseases. For example, the
increasingly detailed genomic map of DNA polymor-
phisms may make it possible to adapt linkage methods,
highly successful for recognized Mendelian syndromes,
to map some genes for non-Mendelian chronic disorders
(Lander and Botstein 1986). However, because of clini-
cal and genetic heterogeneity (Goldin and Gershon
1988), the practical usefulness of linkage analysis in
this setting remains to be determined.
Another well-known strategy for testing the hypothe-
sized association of a "candidate allele" with a disease
is to compare the allele frequency among diseased per-
sons with the frequency in a well or control population
(Cooper and Clayton 1988). Establishing an associa-
tion through such population studies is easy when the
association is very strong and the population frequency
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of the candidate allele is sufficiently high, as for anky-
losing spondylitis and HLA B27 (Ebringer 1980). In
many instances, however, different population studies
have yielded conflicting results for potentially impor-
tant associations, such as those of constitutive h-ras
variants with specific cancers (Krontiris et al. 1985;
Gerhard et al. 1987). Establishing gene-disease associ-
ations promptly and reliably is important for identifying
persons at high risk for the disease and for elucidating
the biochemical mechanisms, including gene-environ-
ment interactions, underlying the disease.
We developed an alternative method, described be-
low, for assessing gene-disease associations for non-
Mendelian disorders when we sought the most efficient
strategy for using molecular methods to identify mu-
tant alleles in a specific setting: testing the predisposi-
tion of ataxia-telangiectasia (A-T; a cancer-prone au-
tosomal recessive syndrome) heterozygotes to specific
cancers (Swift et al. 1987, 1990). This new method
is general in that it applies to any hypothesized gene-
disease association; it has specific advantages over al-
ternative strategies.
General Method
Consider an autosomal locus at which there are two
alleles, A and a. Further suppose that the rarer allele,
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a, has been hypothesized to be associated, in the het-
erozygous state Aa, with disease D. Disease D typically
would be a non-Mendelian common disease such as
a specific cancer, mental illness, or diabetes mellitus.
Such disorders rarely show clear Mendelian patterns
in families; for a common disease in which a typical
Mendelian pattern is evident, linkage analysis is more
suitable than our proposed method. Select, from the
population in which you wish to test the association
of a with D, a sample of N' unrelated index individuals
who are heterozygous or homozygous for allele a. The
index individuals may be homozygous or heterozygous
for the allele, since they serve only to identify families
in which the allele is segregating; index individuals, who
may be found through a population survey, need not,
and typically will not, have disease D.
The next step is to compile pedigrees with reliable
clinical information for each of the N' families identified
through the index individuals heterozygous or homozy-
gous for a. Using the clinical information, selectN blood
relatives who have disease D from the N' families, with
the following rules. The selected diseased blood rela-
tive cannot be an index person. Select only one dis-
eased blood relative from the family of each Aa index
person. If the index person is aa and his parents are
not related, one individual with disease D may be
selected from the maternal and one from the paternal
lineage; this is because allele a is segregating in each
lineage and the allele status of each maternal relative
is independent of that of each paternal relative. Then,
for each of the N selected blood relatives with disease
D, determine his or her genotype at the locus.
The observed proportion of these N diseased rela-
tives with genotype Aa is then compared to the propor-
tion expected from the familial relationships and from
the (assumed to be known) population gene frequency
q (O < q < .5) of a. A statistically significant elevation
of the observed over the expected proportion provides
evidence in" support of an association between disease
D and Aa status. For most chronic diseases, the ob-
served odds ratio estimates reasonably well the relative
risk, which is the ratio of the risk of disease for Aa
carriers to the risk for AA noncarriers.
Null Probabilities of Being Heterozygous for
Allele a for Blood Relatives of a Known Aa
Heterozygote or aa Homozygote
We will consider three scenarios: (1) the index sub-
ject is an Aa heterozygote; (2A) the index subject is an
aa homozygote who is clinically normal; (2B) the in-
dex subject is an aa homozygote and aa homozygotes
are all clinically abnormal (or, aa is "genetically lethal").
Scenario 2B applies when the index individuals all have
a specific autosomal recessive syndrome, such as A-T.
The individuals with the syndrome need not have dis-
ease D, although it is likely that they themselves do have
a high risk of developing it. For the first two scenarios,
standard methods (Li and Sacks 1954; Campbell and
Elston 1971) provide exact expressions (functions of
q; see table 1, parts A and B) for the conditional proba-
bilities that blood relatives of the index subject are Aa
assuming random mating and that no mating pair has
genes identical by descent. These probabilities are the
proportions of the diseased blood relatives that are ex-
pected to be heterozygous for allele a under the null
hypothesis ofno association between the heterozygous
state Aa and disease D. Standard conditional probabil-
ity arguments are used to derive the null probabilities
under scenario 2B (table 1, part C), in which the rare
aa relative will be readily recognized and excluded from
the analysis because he or she will have the distinctive
phenotype of the autosomal recessive syndrome of the
index individuals.
Tests of significance and related assessments of sta-
tistical power depend on these null probabilities. Table
1 shows that inaccuracy in the measurement of q is un-
likely to affect statistical inferences in most practical
circumstances. First, even varying q twofold to fivefold
has little effect on the null probabilities for close rela-
tives of the index individual (e.g., parents, children, and
siblings in scenario 1). Second, for almost all degrees
of relationship, there is little variation in the null prob-
abilities for all values of q < .03. The population fre-
quencies of hypothesized disease-predisposing alleles
typically fall in this range. The accuracy of the mea-
surement of q is of much greater importance for allele
frequencies higher than 0.03 and when relatives as dis-
tant as first cousins are included in the sample. For al-
leles whose frequency is 0.10 or higher and somewhat
uncertain, alternatives to our method should be used
to test hypothesized associations. If the source popula-
tion is composed of two or more subpopulations with
widely discrepant values of q, it is appropriate to ana-
lyze such subpopulations separately.
If allele a predisposes heterozygotes to a common
disease, it is likely that aa homozygotes are also pre-
disposed to the same common disease. However, in most
practical applications, q will be small, and homozy-
gous blood relatives will be encountered rarely. When
it is of interest to examine both the Aa and aa geno-




Conditional Probability of Heterozygosity
A. Conditional Probability 0 That a Relative of a Known Het-
erozygote (Aa) Is Heterozygous (Aa) for Selected Values of
q in the Population under Study (Scenario 1)a
Second-Degree First
q Siblingb Relativec Cousind
.001 ..... .5005 .2510 .1265
.005 ..... .5025 .2550 .1325
.010 ..... .5049 .2599 .1399
.030 ..... .5145 .2791 .1687
.050 ..... .5237 .2975 .1963
.100 ..... .5450 .3400' .2600
.200 ..... .5800 .4100 .3650
B. Conditional Probability 0 That a Relative of a Clinically Nor-
mal Homozygote (aa) Is Heterozygous (Aa) for Selected Values
of q in the Population under Study (Scenario 2A)
Child or Second-Degree First
q Parente Siblingf Relativeg Cousinh
.001 ..... .9990 .5000 .5005 .2512
.005 ..... .9950 .5000 .5025 .2562
.010 ..... .9900 .4999 .5049 .2623
.030 ..... .9700 .4996 .5141 .2862
.050 ..... .9500 .4988 .5225 .3088
.100 ..... .9000 .4950 .5400 .3600
.200 ..... .8000 .4800 .5600 .4400
C. Conditional Probability 0 That a Relative of a Clinically Ab-
normal Homozygote (aa) Is Heterozygous (Aa), Conditional on
Such Relatives and Their Mates Not Being aa, for Selected
Values of q in the Population under Study (Scenario 2B)'
Aunt or Niece or First
q Grandparenti Unclek Nephewl Cousinm
.001 ..... .5005 .5001 .3338 .2506
.005 ..... .5025 .5006 .3355 .2531
.010 ..... .5050 .5013 .3377 .2562
.030 ..... .5150 .5038 .3464 .2683
.050 ..... .5250 .5063 .3548 .2800
.100 ..... .5500 .5128 .3750 .3079
.200 ..... .6000 .5263 .4118 .3578
a The conditional probability that a parent or child of a known
heterozygote (Aa) is heterozygous (Aa) is .5, independently of q.
b (1 + q - q2)/2.
c (1 + 4q - 4q2)/4 (grandparent, aunt, uncle, niece or nephew).
d (1 + 12q - 12q2)/8.
e (1 - q).
f (1 - q2)/2.
g (1 + q - 2q2)12.
h (1 + Sq - 6q2)/4.
' Under Scenario 2B, the conditional probabilities that a parent
and a sibling of the index person are heterozygous (Aa) are 1.0 and
2/3, respectively, independently of q.
i (1 + q)/2.
k 2/(4 - q).
(1 + 2q)/(3 + 2q).
m (1 + 3q - q2)/(4 + 2q - q2).
the disease under study, appropriate modifications can
be made to the binomial-based analysis discussed be-
low for the Aa genotype.
Statistical Inference and Sample-Size
Considerations
As stated earlier, to avoid certain dependency-related
complications, our proposed study design dictates
choosing exactly one blood relative (of any type) with
disease D for each identified Aa heterozygote (or one
diseased maternal relative and one diseased paternal
relative of each aa homozygote).
Probability Model
For the ith diseased blood relative (i = 1,2, .
N), define the dichotomous random variable Ri to be
1 if the ith diseased blood relative is heterozygous (Aa),
and 0 if not. Note that Ri = 0 if the ith diseased blood
relative is either AA or aa under scenarios 1 and 2A.
The aa genotype in relatives is excluded under scenario
2B, since these relatives will have the distinctive pheno-
type of the autosomal recessive syndrome in the index
individuals.
Now, let Oi = pr (RA =1 D). And, under Ho (no
association between being a heterozygote and disease
risk), let Ooi denote the null value of Oi. Given the
familial relationship of the ith selected diseased blood
relative and the known value of q, the specific numeri-
cal value of Ooi (the null probability that this ith blood
relative is heterozygous Aa) is determined using the
methods of the previous section. Under HA (positive
association between being a heterozygote and disease
risk), Oi is greater than Ooi for i = 1,2, . . . , N. The
methods to be developed apply also to testing for a pro-
tective, as opposed to a detrimental, effect of heterozy-
gosity. When an allele protects against disease D, Oi is
less than Ooi for i = 1,2, . . . , N.
The effect measure of interest will be the odds ratio
0,1/(1 - 0,)= 00/(1 _ 0,) , where 0 < 4 < +0.
This odds ratio will not depend on i unless other risk
factors for disease D are nonrandomly distributed with
respect to allele a. Note that
0' - 1 + Ooi(4 - 1)'




0N i 1 1 + OOi(O - 1)
In terms of 4, the null hypothesis of interest is Ho:0=1
and the alternative hypothesis is either HA:X>1 for a
hypothesized detrimental effect of heterozygosity or
HA:OA<1 for a protective effect.
Maximum-Likelihood Methods
Since the Ri's are mutually independent 0-1 random
variables, the likelihood function L for these data is
i 1 +K ,(O - 1)1
X (1 - 00i) 11 - Ri
L1 + 0oi(O - 1)]
Equating dlnL/do with zero gives 4, the maximum-
likelihood estimator of 4, as the solution to the likeli-
hood equation
N 1
i = 1 i~l 1 + oi(4)- 1'1, (1)
In general, equation (1) must be solved iteratively. A
good starting value for this iteration process is
Power and Sample-Size Considerations





Var(RIHo) = N-2 E OOi(l - Ooi)
i= 1
is the variance of R under Ho. Under Ho, this test
statistic will have an approximate standard normal dis-
tribution for moderate to large N. Hence, the approxi-
mate power of a size a test of Ho:) = 1 versus HA:0>1
equals
pr {(R - Oo) > Zi - aI > 11
I[N-2 F, 00i(l _ 00i)]1',
i=l
where pr (Z > Z1 -a) = a when Z - N(0,1). Thus, to
achieve a power of at least (1 - I), standard statistical
arguments dictate that N should be the smallest posi-
tive integer satisfying the inequality
R/(1 - R)
Oo/(l - Oo)
where R is the observed proportion of diseased blood
relatives who are heterozygous and Oo is the expected
value of R under Ho, or
N N
R= N-1iE Ri, and o = N-1 Ooi.
Since [ln) - lnO]/[Var(ln+)]½/I is approximately
N(O,1) for moderate to large N (Woolf 1955), where
Var(lno) is the estimated variance ofln4, it can be shown
that an approximate 100 (1- a)% confidence interval
for 4 is
4 exp [± Zl-/2 [Var(ln+)]1/2} (2)
where Z1- a/2 is the 100(1- a/2) percentile point of the
standard normal distribution and where
VAr Nn¢)=i o(<oi) 1Var(In4)) = E (3~i= [1 + 0oj(~-j)]23 ()
N N








NO(1 - 0) T, O(1 - 0,),
i= 1
an upper bound for N is that positive integer, say N*,
satisfying the inequality
[Zi>[ a[00(j - o0)]½2 + Zjp[0(j - 0)]1/2]2
( 0~0o)2
Let us assume that 0- [40o] / [1 + Oo() -1)]
This assumption is exactly true when the diseased blood
relatives are all of the same type. In most practical situ-
ations, the absolute difference between the exact and
approximate values of 0 should be less than OS.
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Combining the above approximation with the previ-
ous inequality involving N* gives the inequality
[Zi_ a[1 + Oo() - 1)] + Zi - 54½} . (4)
The motivation behind the development leading to
expression (4) is now apparent. To use expression (4)
to help design a study of the kind we are advocating
(i.e., to obtain an approximate idea of the needed num-
ber N* of diseased blood relatives), it is only necessary
to specify values for the following quantities: a, the
size of the rejection region for a one-sided test of
Ho:0=1 versus either HA:q6>1 or HA:4<1; (1 - 1), the
desired power of the test; X, the anticipated value of
the population odds ratio (a value greater than 1 for
a detrimental effect of being a heterozygote, and a value
less than 1 for a protective effect); and Oo, the mean of
the N Ooi values based on the types of diseased blood
relatives likely to be chosen and on the value of q. Table
2 contains values of N* based on (4) for some combi-
nations of values of a, (1 - I), 4, and Oo. When the
anticipated true value of is greater than 2.0, note that
N* does not vary much with changes in go. Table 2
also demonstrates that a relatively small increase in
sample size results in a significant increase in power.
Also, from expression (4) and from the entries in ta-
ble 2, it is clear that, for a given value of 4, the required
sample size increases as Oo gets closer to zero. Hence,
our proposed "enrichment process" of making the null
probabilities of heterozygosity larger than 2q(1 - q)
via the use of relatives of index persons known to carry
allele a leads to a statistically powerful design.
Finally, for fixed values of a, 1, and 4, the choice
of Oo, say Oo*, which minimizes the right-hand side
of inequality (4) is
* [1 + (Zi-aO + Z1_ 4))1-1
~~(Zi-a + Zi-001/2))J
Since this optimal Oo* varies inversely with 4, the
power of our method to detect the effects of genes that
protect against a disease is much greater when the per-
sons with disease D are close, rather than more distant,
relatives of the index individuals (table 2, part B).
Illustrative Example
The following hypothetical example shows how the
proposed methodology will be used to assess whether
females heterozygous for the A-T gene are at elevated
risk for developing breast cancer (Swift et al. 1987) when
there is a reliable test for the A-T heterozygote. The A-T
Table 2
Power-based Sample-Size Requirements
A. Sample Sizes (N*) from Equation (4) Required to Test H.:4=1 versus HA:0>1 with Power at Least (1 - 1) for a = .01,
for Selected Values of the Odds Ratio (O), and of the Expected Proportion of Heterozygotes under the Null Hypothesis (6O)
1 - = .75 1 -1 = .80 1 - = .85
+ 60 = .15 0= .30 60 = .55 60 = .15 6o = .30 00= .55 60 = .15 0= .30 o= .55
1.5 348 234 233 392 262 259 445 296 290
2.0 104 76 84 118 85 93 135 96 104
2.5 54 42 51 61 47 56 70 54 63
3.0 35 29 37 40 32 41 46 37 45
3.5 25 22 30 29 25 33 34 28 36
4.0 20 18 26 23 20 28 26 23 31
4.5 16 15 23 19 17 25 22 19 27
5.0 14 14 21 16 15 23 18 17 25
B. Sample Sizes (N*) from Equation (4) Required to Test Ho:+= 1 versus HA:4<1 with Power at Least (1 - I) for a - .01,
for Selected Values of the Odds Ratio (0), and of the Expected Proportion of Heterozygotes under the Null Hypothesis (0o)
1 - = .75 1 -1 = .80 1 - = .85
4 60= .15 o= .30 60= .55 ;0= .15 0o= .30 60= .55 60 = .15 0 =.30 O= .55
.25 81 39 21 87 42 23 93 46 26
.50 217 115 76 237 126 85 261 140 95
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gene has been mapped to chromosome 11q22-23 (Gatti
et al. 1988), so that A-T heterozygotes can be identified
in A-T families once closely linked markers or allele-
specific probes become available.
Suppose that MN = 60 families of A-T homozygotes
are surveyed and that 10 grandmothers and 10 aunts
with breast cancer are found. Assuming that q = .01,
then the null probabilities of heterozygosity for the
grandmothers and aunts are, respectively, (1 + q)/2
= 0.5050 and 2/(4 - q) = 0.5013 (see table 1, part
C). Hence Oo = .5031 and Var(RIHo) = .0125.
If EZ= 1 Ri = 16 of these N = 20 female breast
cancer cases are found to be heterozygous for the A-T
gene, then R = 16/20 = .80. The score statistic value is
(.80 - .5031)/(.0125)1/2 = 2.66 (P .004), indicat-
ing a highly significant association for these data.
From expression (1), the maximum-likelihood esti-
mate + of the population odds ratio is = 3.95.
And, from expressions (2) and (3), an approximate 95%
confidence interval for is (1.32, 11.82).
Comparison with an Alternative Strategy
We have compared sample-size requirements based
on expression (4) to those for a study design that is
the most realistic competitor to the design we have pro-
posed. The obvious alternative design is the 1-to-M
matched case-control design, where each case is a fam-
ily member with the disease of interest, each set of M
controls consists of M randomly chosen nondiseased
blood relatives for each case, the dichotomous exposure
outcome variable pertains to being heterozygous or not,
and the basic matching variable pertains to family mem-
bership.
The differences between sample-size requirements
based on expression (4) and those based on the stan-
dard conditional analysis of 1-to-M matched data (Bres-
low and Day 1987, table 7.9) are so large that adjust-
ments for possible intrafamilial correlation effects (Liang
1985) would not alter the obvious conclusion. In par-
ticular, for a = .05, (1 - 1) = .80, and Oo = .30,
table 3 illustrates that the N* values are much less than
the corresponding N+ values of Breslow and Day,
where the required number of 1-to-M matched case-
control sets equals N+ /(M + 1).
One obvious reason for the large discrepancies be-
tween the N* and N+ values is the statistical fact that
the value of q (or, equivalently, Oo) is assumed
to be known when determining N*, while N+ reflects
the necessity to estimate background rates.
Table 3
Sample-Size Requirements for a = .05, (I - 1) = .80, and
;. = .30 Using our Proposed Method (No)
Compared to l-to-M Matched Data Method (N+)
N + VALUES
ODDS RATIO N*VALUES M=1 M=2 M=4
1.50 163 710 792 1,095
2.00 53 244 270 370
2.50 30 142 156 215
3.00 20 100 111 150
3.50 16 78 87 115
4.00 13 64 72 95
4.50 11 56 60 85
5.00 10 50 54 75
NOTE.- For a discussion of the 1-to-M matched data method, see
Breslow and Day (1987, chap. 7).
Other Characteristics of this Method
Effects of Sample Stratification and of Other Risk Factors
Undetected stratification is likely to affect population-
based tests of associations but not our proposed meth-
od, even though there is no explicit control group
matched, for potential confounders, to the diseased rela-
tives. In our method, the individuals with the disease
D are selected from the extended families of the index
individuals. Within either the maternal or paternal fam-
ily ofeach index individual, heterozygotes and nonhet-
erozygotes for allele a are first-, second-, and third-degree
relatives who share both a high proportion of their other
genes and the familial environment, including ethnic
origins and socioeconomic status (SES). Alleles at other
loci and environmental risk factors (unless causally
related to the allele) are expected to be distributed ran-
domly among allele a heterozygotes and nonheterozy-
gotes in each family. In general, selection bias is un-
likely because relatives with disease D are chosen
without any knowledge of their status at the locus of
interest.
Using the example of an association between allele
a and breast cancer, consider how risk factors such as
SES or parity might influence the assessment of this
association. Any risk factor is either distributed ran-
domly with respect to allele a in each family, or it is
not. If the risk factor is randomly distributed with re-
spect to allele a, the association cannot be influenced
by the factor. Suppose, on the other hand, that allele
a predisposes to low parity, which in turn predisposes
to breast cancer. Then an association between allele
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a and breast cancer will be found. This is a true associ-
ation, mediated through the effect of allele a on parity.
Establishing a gene-disease association does not expli-
cate its biological mechanism, which must be deter-
mined from further studies or from information already
available about how the gene acts.
A true association between allele a and breast cancer
might be missed only if the allele had two opposing
effects. The allele might predispose to the cancer on
the basis of some cellular mechanism related to tumor
growth, and also predispose to high parity, which re-
duces the chance that a breast cancer will develop. This
unlikely situation would be detected only by compar-
ing the parity of allele a heterozygotes to nonhetero-
zygotes in the families.
Our proposed strategy can be adapted to test hypoth-
eses of the form "allele a is associated with significant
excess mortality (Schiliro et al. 1989) by (or enhanced
survival to) age A' by selecting at random from the family
of each index individual one living person slightly older
than age A. If allele a leads to excess mortality, the ob-
served proportion of allele a heterozygotes in this group
will be less than expected. Hypotheses about the effect
of specific alleles on mortality are, of course, of sub-
stantial biological interest. If such an effect is suspected,
it is important to detect and evaluate it before evaluat-
ing hypotheses about the allele and a specific disease,
since tests of the latter association could be misleading
if the allele differentially affects mortality.
When there is incomplete cooperation from the
selected set of relatives with disease D, the observed
odds ratio will be unbiased unless the allele a influences
the chance that a relative will be available to, or cooper-
ate in, the study. Thus, if allele a is associated with
a severe personality disorder, the sample ofN individu-
als with disease D might not accurately represent the
proportion of allele a heterozygotes in the population
of interest. This potential source of bias must always
be taken into account in testing hypotheses about al-
leles that predispose to mental disorders.
While the selection of index individuals can be ar-
bitrary, it is important, since this set of individuals
defines the source population. For example, if the in-
dex individuals are selected from a population in which
there are two subpopulations, in one of which the al-
lele a is not present, then the assessment of heterozy-
gote risk will apply only to the subpopulation in which
it is prevalent. As always, any association found in one
population should be generalized with great care to
other populations.
Another way in which the test of an association de-
pends on the source population is illustrated by the test
of the hypothesized h-ras breast-cancer association in
a set of families in which three or more first- or second-
degree relatives have had breast cancer (Hall et al. 1990).
In these families the breast cancers may result from a
gene or environmental factor whose effect is so pro-
nounced that effects of alleles at the h-ras locus are not
detectable. On the other hand, if the IN families are
selected from a general population and the observed
proportion of heterozygotes is compared to that ex-
pected in this sample, then a positive association of the
h-ras allele with breast cancer might be detected.
Specificity of the Hypothesis
The particular group of relatives with disease D will
specify the disease phenotype whose association with
allele a is being tested. For example, if disease D is breast
cancer and all relatives with breast cancer in the partic-
ular sample have had premenopausal onset, then the
observed proportion who are heterozygous for allele
a pertains only to the association of a with premeno-
pausal breast cancer.
Detecting Genes That Protect Against Disease
The power of this proposed method is particularly
great when compared to that of population tests of as-
sociations for disease-protecting effects of specific al-
leles, because, for population tests, the allele frequency
must be determined in a very large sample of diseased
persons if a significant deviation downward from the
general population frequency is to be found (Fleiss
1981).
Indifference to Genetic Heterogeneity
It is likely that alleles at several or many different loci
predispose to a specific common disease such as breast
cancer. Since the statistical power of the method we
propose for testing the association of a single allele with
the common disease depends only on the frequency of
that particular allele and the strength of the associa-
tion (as measured by 4), this power is not affected by
the presence of disease-predisposing alleles at other loci.
The power of linkage analysis to detect a single locus
involved in the etiology of a common disease is, on the
other hand, greatly influenced by the degree of under-
lying genetic heterogeneity (Lander and Botstein 1986;
Goldin and Gershon 1988) unless a single large pedi-
gree is studied.
Availability of Appropriate Families
For some studies of alleles hypothesized to predis-
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pose heterozygotes to common diseases, sets of fami-
lies in which an allele is segregating have already been
identified or can be easily identified. For example, clin-
ical information about relatives has already been col-
lected for about 200 families of A-T patients (Swift et
al. 1990). Any hypothesis about a specific cancer that
may be associated with A-T heterozygosity can be tested
rapidly by collecting DNA from the blood relatives with
that cancer and determining the proportion of A-T het-
erozygotes. Because of an excess of cancer in families
of retinoblastoma patients (Strong et al. 1984), the ret-
inoblastoma allele has been hypothesized to predispose
to certain other specific cancers. This hypothesis could
be tested with convincing rigor in families with ret-
inoblastoma by the method we are proposing. Conflict-
ing analyses of disease-predisposition associated with
alphai-antitrypsin deficiency heterozygosity (Hutch-
inson 1988) could be definitively resolved in families
of known homozygotes. On the other hand, for alleles
at some loci, surveys of defined populations may be
necessary to assemble the set of N' families in which
the allele is segregating.
A sample of families appropriate to our method can
also be constructed conveniently by beginning with a
set ofDNA samples, from individuals with disease D,
from which allele status could be determined. An ex-
ample would be a set of stored specimens from patients
who have had a breast cancer. For each specimen, find
a living relative and determine first if that relative is
heterozygous for the allele of interest. For each of the
N relatives found to be heterozygous, then, and only
then, test the allele status of the corresponding breast-
cancer relative, and compare the observed to the ex-
pected proportion as described above.
Availability of DNA Samples
When assessing the heterozygosity status of the rela-
tives with disease D, blood is the most convenient source
ofDNA. For diseases with a high mortality rate, it will
be possible to use formalin-fixed tissue from surgical
or autopsy specimens. Although DNA in such speci-
mens is often too degraded for Southern blots (Dubeau
et al. 1986), the presence of a specific allele can usually
be determined with the polymerase chain reaction (PCR)
(Burmer et al. 1989). This determination should be done
on noncancerous tissue whenever possible, since there
may be allele loss in cancers.
Conclusion
When testing hypotheses about the association of
specific alleles with common chronic diseases, results
using this statistically powerful method are unlikely to
be influenced by confounders, systematic bias, or genetic
heterogeneity.
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